Core Insights - IBA has signed a contract with Steri-Tek to install a Be Wide X-ray Solution, enhancing Steri-Tek's sterilization capabilities [1][3] - The new system will increase Steri-Tek's processing capacity fivefold, allowing for the sterilization of full pallets and improving throughput [2][3] - The Be Wide X-ray Solution is expected to be operational by the end of 2027, with costs ranging from EUR 16 million to EUR 19 million [3] Company Overview - IBA is a leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people globally [6] - Steri-Tek is a high-volume E-beam/X-Ray contract sterilizer serving various industries, with facilities in California and Texas, and is certified in multiple quality standards [7]

STERIS plc (STE) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.74, up 13.7% from the year-ago quarter’s figure. The figure surpassed the Zacks Consensus Estimate by 5.8%.The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.The company’s GAAP EPS was $1.48, down 3.9% from the year-ago level of $1.54.  Full-year fiscal 2025 adjusted EPS was $9.22, up 12.4% from ...

Core Viewpoint - American Shared Hospital Services reported a 17% year-over-year revenue growth for Q1 2025, driven by strategic expansions and operational strengths despite some declines in treatment volumes [4][6]. Financial Performance - Revenue for Q1 2025 was $6.1 million, up from $5.2 million in Q1 2024, primarily due to expanded radiation therapy services [4][6]. - Direct patient services revenue surged by 224% to $3.1 million, attributed to the acquisition of Rhode Island centers and the new facility in Puebla, Mexico [4][6]. - Revenue from the medical equipment leasing segment decreased to $3.0 million from $4.3 million, influenced by lower Gamma Knife volumes and contract expirations [5][6]. Operational Highlights - The company experienced a gross margin of $942,000 in Q1 2025, down from $2.1 million in Q1 2024, mainly due to lower treatment volumes [7]. - A net loss of $625,000 was reported for Q1 2025, compared to a net income of $119,000 in the same period last year [7][16]. - Adjusted EBITDA for Q1 2025 was $0.9 million, a decrease from $1.7 million in Q1 2024 [8][18]. Strategic Initiatives - The company is optimistic about future growth, with plans for further acquisitions and operational efficiencies to enhance profitability [3][6]. - New facilities in Rhode Island and Mexico are expected to contribute to long-term growth, with a focus on expanding direct patient care services [3][4]. Balance Sheet Overview - As of March 31, 2025, cash and cash equivalents totaled $11.5 million, slightly up from $11.3 million at the end of 2024 [9][17]. - Shareholders' equity was reported at $24.6 million, down from $25.2 million at the end of the previous year [9][17].

Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue fr ...

Core Viewpoint - American Shared Hospital Services (AMS) is set to discuss its first quarter 2025 financial results in a conference call scheduled for May 15, 2025, at 12:00 pm ET [1]. Financial Results Announcement - The financial results press release for the first quarter of 2025 will be issued before the market opens on May 15, 2025 [2]. Teleconference and Webcast Information - Domestic callers can join the call by dialing 1-844-413-3972, while international callers can dial 1-412-317-5776, at least 10 minutes prior to the start [3] - A simultaneous webcast will be available on the company's website [3] - A replay of the call will be accessible until May 22, 2025, through specified phone numbers and the company's website [3] Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers, health systems, and cancer networks in North and South America [4] - The company collaborates with partners to enhance cancer service lines and provide integrated care close to patients' homes [4] - AMS shares capital investment costs and profitability with health system partners based on ownership interests [4]

May 9, 2025 05:51 AM GMT Shenzhen New Industries | Asia Pacific China BEST Conference 2025 Feedback Key Takeaways Targeting single-digit China growth for 2025, with faster analyzer than reagent growth: For analyzer installations, SNIBE continues to target 2,000 units (¾ being high throughput models) and 200 TLAs in 2025. Reagent ASP should have bottomed in 2Q25 (~5% QoQ decline from 1Q25) hence the YoY price impacts will be largely digested by 4Q25. As for volume, mgmt expects sequentially improving volume ...

Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providersSAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to ...

Core Insights - Thermo Fisher Scientific Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate by 1% and reflecting a year-over-year increase of 0.8% [1] - The company's GAAP EPS was $3.98, marking a 15% increase year over year [1] - Following the earnings announcement, shares of Thermo Fisher rose 1.7% in pre-market trading [2] Revenue Performance - Total revenues for the quarter reached $10.36 billion, a 0.2% increase year over year, surpassing the Zacks Consensus Estimate by 1.1% [3] - Organic revenues increased by 1% year over year [3] Segment Analysis - Life Sciences Solutions segment (22.6% of total revenues) saw revenues increase by 2.4% year over year to $2.34 billion, exceeding estimates [4] - Analytical Instruments segment (16.6%) reported a 1.8% year-over-year increase in revenues to $1.72 billion, which fell short of estimates [5] - Specialty Diagnostics segment (11.1%) experienced a 3.5% year-over-year revenue increase to $1.15 billion, surpassing predictions [6] - Laboratory Products and Biopharma Services segment (54.4%) saw a decline of 1.4% year over year, with revenues at $5.64 billion, slightly below estimates [7] Margin Performance - Gross margin for the first quarter was 41.6%, contracting by 5 basis points year over year due to a 0.3% rise in the cost of revenues [8] - Selling, general and administrative expenses decreased by 0.6% to $1.72 billion, while research and development expenses increased by 3.3% to $342 million [8] - Adjusted operating margin was 21.7%, reflecting a contraction of 2 basis points [8] Financial Position - At the end of Q1 2025, cash and cash equivalents and short-term investments totaled $5.95 billion, up from $5.57 billion at the end of Q4 2024 [9] - Net cash from operating activities was $723 million, down from $1.25 billion a year ago [10] - The company has a consistent dividend-paying history, with a five-year annualized dividend growth of 15.10% [10] Strategic Developments - During the first quarter, Thermo Fisher launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal proteomics kits, contributing to commercial success [12] - The company announced an agreement to acquire Solventum's Purification & Filtration Business for $4.1 billion in cash [12] Overall Assessment - Thermo Fisher's first-quarter results exceeded expectations in terms of earnings and revenues, with growth in most segments except for Laboratory Products and Biopharma Services [11] - The contraction in margins was noted as a concern, and the company is expected to provide guidance for 2025 in an upcoming earnings call [11]

InfuSystem Holdings, Inc. (NYSE:INFU) Q4 2024 Results Conference Call March 4, 2025 9:00 AM ET Company Participants Joe Dorame - Managing Partner Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Kyle Bauser - B. Riley Securities Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings, Inc. Reports fourth quarter and full ye ...